Clinical Trials
Tirzepatide Linked With Greater Lean Body Mass Loss Than Semaglutide in Routine Care
Murugadoss et alnpj Exercise Medicine and Health

In an observational cohort study evaluating 670,422 first-time users of semaglutide or tirzepatide via an EHR-linked, LLM-enabled body-composition phenotyping pipeline, 7,965 patients had paired pre- and post-treatment measurements over a 12-month period.
Unadjusted analyses revealed that tirzepatide was associated with a greater relative decline in lean body mass (LBM) compared to semaglutide at 12 months, with a difference of −2.1 percentage points (95% CI −3.8 to −0.3). However, this between-drug disparity was abolished following adjustment for concurrent total weight loss (−0.1 percentage points, 95% CI −1.6 to 1.4). Across both incretin therapies, LBM loss accounted for approximately 20% of total weight lost, indicating that lean tissue reduction scales directly with overall weight loss depth.
Subgroup phenotyping showed that the exploratory Depletive GLP-1 phenotype—defined as greater than 20% total body weight loss accompanied by greater than 5% LBM loss—occurred more often in tirzepatide-treated individuals than in semaglutide-treated individuals (10.3% vs 6.7%, P < 0.001). Conversely, the Prime phenotype, characterized by less than 5% LBM loss alongside greater than 10% total body weight reduction, presented at comparable frequencies between cohorts (11.8% for tirzepatide vs 12.3% for semaglutide, P = 0.66).
Functionally, patients experiencing greater LBM loss had an increased frequency of documented reduced exercise tolerance, noted at rates 7.2 and 11.1 percentage points higher in semaglutide- and tirzepatide-treated groups, respectively. The authors concluded that because LBM loss scaled with weight reduction and showed broad inter-individual variability, these findings support prospective assessment of body-composition metrics during incretin therapy.
Key Takeaways
- Tirzepatide was associated with greater relative lean body mass loss than semaglutide at 12 months (difference: −2.1 percentage points; 95% CI, −3.8 to −0.3), but this difference attenuated after adjustment for concurrent weight change (−0.1 percentage points; 95% CI, −1.6 to 1.4), with lean mass accounting for approximately 20% of lost weight with either agent.
- The exploratory depletive phenotype (>20% total weight loss with >5% lean body mass loss) occurred more frequently in patients receiving tirzepatide compared with semaglutide (10.3% vs 6.7%, P < 0.001), whereas the prime phenotype (<5% lean mass loss with >10% total weight loss) occurred at similar rates (11.8% vs 12.3%, P = 0.66).
- Greater lean body mass loss was clinically relevant, with reduced exercise tolerance documented 7.2 and 11.1 percentage points more frequently in semaglutide- and tirzepatide-treated cohorts, respectively.
Read the original sourcenpj Exercise Medicine and Health
